Your browser is no longer supported. Please, upgrade your browser.
Settings
OTLK [NASD]
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own12.80% Shs Outstand150.73M Perf Week-6.61%
Market Cap402.03M Forward P/E- EPS next Y-0.22 Insider Trans97.57% Shs Float89.63M Perf Month-9.24%
Income-40.50M PEG- EPS next Q-0.07 Inst Own9.00% Short Float3.51% Perf Quarter-5.04%
Sales- P/S- EPS this Y66.00% Inst Trans1.43% Short Ratio3.45 Perf Half Y141.69%
Book/sh0.14 P/B16.14 EPS next Y29.00% ROA-150.50% Target Price- Perf Year63.77%
Cash/sh0.21 P/C10.81 EPS next 5Y- ROE-675.90% 52W Range0.58 - 4.26 Perf YTD73.85%
Dividend- P/FCF- EPS past 5Y43.50% ROI- 52W High-46.95% Beta0.70
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low289.66% ATR0.15
Employees8 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)43.03 Volatility7.52% 6.58%
OptionableNo Debt/Eq0.55 EPS Q/Q76.10% Profit Margin- Rel Volume0.69 Prev Close2.41
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume911.15K Price2.26
Recom2.00 SMA20-6.63% SMA50-9.09% SMA20021.42% Volume630,027 Change-6.22%
Sep-11-19Initiated Ladenburg Thalmann Buy $9
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
Jul-07-21 08:05AM  
Jul-02-21 05:04AM  
Jun-14-21 08:05AM  
Jun-08-21 08:05AM  
May-27-21 08:05AM  
May-18-21 06:15AM  
May-14-21 08:05AM  
May-12-21 08:05AM  
Mar-31-21 09:23AM  
08:05AM  
Mar-23-21 04:49AM  
Mar-04-21 09:00AM  
Feb-17-21 08:05AM  
Feb-16-21 08:05AM  
Feb-11-21 08:05AM  
Feb-04-21 11:18AM  
09:05AM  
Feb-02-21 04:05PM  
Jan-28-21 11:59PM  
05:35PM  
Jan-12-21 08:05AM  
Jan-05-21 08:00AM  
Dec-23-20 09:05AM  
Dec-07-20 08:04PM  
Dec-01-20 08:05AM  
Nov-19-20 08:05AM  
Nov-11-20 09:05AM  
Nov-05-20 08:05AM  
Nov-03-20 08:35AM  
Oct-22-20 08:00AM  
Oct-13-20 08:05AM  
Oct-12-20 03:30PM  
Oct-07-20 08:05AM  
Sep-30-20 08:05AM  
Sep-08-20 08:05AM  
Aug-26-20 02:52PM  
08:05AM  
Aug-14-20 08:05AM  
Jul-17-20 08:05AM  
Jul-07-20 08:05AM  
Jun-25-20 09:43AM  
08:05AM  
Jun-23-20 08:00AM  
Jun-17-20 08:05AM  
Jun-11-20 08:05AM  
Jun-10-20 08:12PM  
Jun-09-20 08:05AM  
Jun-03-20 08:05AM  
May-26-20 08:05AM  
May-20-20 08:39AM  
May-15-20 08:00AM  
Apr-21-20 08:05AM  
Apr-16-20 09:16AM  
Apr-15-20 08:35AM  
Apr-14-20 08:05AM  
Mar-19-20 09:32AM  
Mar-05-20 08:00AM  
Feb-26-20 02:26PM  
Feb-25-20 09:15AM  
Feb-24-20 08:00AM  
Feb-18-20 01:28PM  
Feb-14-20 08:00AM  
Feb-04-20 08:00AM  
Jan-28-20 08:00AM  
Dec-26-19 08:00AM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-19-19 08:00AM  
Dec-03-19 08:00AM  
Nov-13-19 10:44AM  
Sep-11-19 08:00AM  
Aug-27-19 08:00AM  
Aug-20-19 08:00AM  
Aug-14-19 04:15PM  
Jul-19-19 12:39PM  
Jul-18-19 12:05PM  
Jul-16-19 08:00AM  
Jun-03-19 08:57AM  
08:00AM  
May-24-19 12:50PM  
May-20-19 09:02AM  
May-17-19 03:17PM  
09:47AM  
May-16-19 09:48AM  
May-15-19 08:00AM  
Apr-26-19 08:00AM  
Apr-10-19 09:00AM  
Apr-01-19 08:00AM  
Mar-15-19 09:00AM  
Mar-05-19 08:00AM  
Mar-01-19 08:00AM  
Feb-14-19 08:00AM  
Feb-13-19 11:45AM  
Feb-01-19 09:15AM  
Jan-22-19 09:00AM  
Jan-02-19 09:15AM  
Dec-18-18 09:00AM  
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENYON LAWRENCE ACEO, Pres, CFO, Treas & SecyApr 20Buy1.8310,00018,30018,926Apr 20 07:54 PM
Haddadin Yezan MuntherDirectorApr 19Buy1.8210,00018,20020,000Apr 20 07:56 PM
Sukhtian Faisal GhiathDirectorApr 19Buy1.8210,00018,20020,000Apr 20 07:55 PM
Evanson JeffChief Commercial OfficerFeb 23Sale2.098,55417,8611,141,930Feb 25 08:52 PM
Dagnon TerryChief Operating OfficerFeb 23Sale2.0915,90033,1991,127,857Feb 25 08:51 PM
Evanson JeffChief Commercial OfficerFeb 12Sale2.5556,973145,2811,150,484Feb 17 09:14 PM
Dagnon TerryChief Operating OfficerFeb 12Sale2.5563,700162,4351,143,757Feb 17 09:13 PM
Syntone Ventures LLC10% OwnerFeb 03Buy1.003,000,0003,000,00019,823,045Feb 04 08:54 PM
Sukhtian Ghiath M.DirectorFeb 02Buy1.008,360,0008,360,00010,820,630Feb 02 05:32 PM
Haddadin Yezan MuntherDirectorSep 22Buy0.7210,0007,24510,000Sep 22 05:14 PM
Sukhtian Faisal GhiathDirectorSep 17Buy0.6710,0006,73110,000Sep 17 07:18 PM
THURMAN RANDY HDirectorSep 14Buy0.6210,0006,20011,875Sep 15 06:31 PM